Q1 Earnings Forecast for TNYA Issued By Lifesci Capital

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Lifesci Capital issued their Q1 2026 earnings per share estimates for Tenaya Therapeutics in a research note issued on Thursday, March 12th. Lifesci Capital analyst T. Pardo-Garcia expects that the company will post earnings of ($0.14) per share for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Lifesci Capital also issued estimates for Tenaya Therapeutics’ Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.59) EPS.

Tenaya Therapeutics (NASDAQ:TNYA) last released its quarterly earnings data on Wednesday, March 11th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12).

TNYA has been the topic of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Tenaya Therapeutics in a research report on Wednesday, January 21st. Canaccord Genuity Group lowered their price target on Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. William Blair reissued an “outperform” rating on shares of Tenaya Therapeutics in a report on Thursday. Chardan Capital restated a “buy” rating and issued a $8.00 price objective on shares of Tenaya Therapeutics in a research report on Thursday. Finally, Morgan Stanley set a $2.00 target price on Tenaya Therapeutics in a research note on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $4.00.

Tenaya Therapeutics Stock Performance

Shares of Tenaya Therapeutics stock opened at $0.89 on Friday. The firm has a 50-day simple moving average of $0.73 and a two-hundred day simple moving average of $1.12. The company has a market cap of $146.20 million, a P/E ratio of -1.44 and a beta of 3.22. Tenaya Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $2.35.

Insiders Place Their Bets

In related news, major shareholder Group Gp Lp Column III sold 4,056,573 shares of Tenaya Therapeutics stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $0.68, for a total transaction of $2,758,469.64. Following the transaction, the insider owned 2,348,183 shares in the company, valued at approximately $1,596,764.44. This trade represents a 63.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders have sold 8,594,047 shares of company stock valued at $5,430,207. Company insiders own 48.65% of the company’s stock.

Institutional Trading of Tenaya Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TNYA. Mirador Capital Partners LP raised its position in shares of Tenaya Therapeutics by 38.2% during the 3rd quarter. Mirador Capital Partners LP now owns 23,500 shares of the company’s stock valued at $38,000 after buying an additional 6,500 shares during the period. Scientech Research LLC purchased a new position in Tenaya Therapeutics in the third quarter worth approximately $27,000. Geode Capital Management LLC grew its position in Tenaya Therapeutics by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 1,193,355 shares of the company’s stock worth $849,000 after acquiring an additional 17,820 shares during the period. Cetera Investment Advisers increased its stake in Tenaya Therapeutics by 107.0% during the fourth quarter. Cetera Investment Advisers now owns 106,425 shares of the company’s stock worth $76,000 after acquiring an additional 55,000 shares during the last quarter. Finally, Jefferies Financial Group Inc. purchased a new stake in Tenaya Therapeutics in the third quarter valued at $99,000. Institutional investors and hedge funds own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.